Vanda Pharmaceuticals (VNDA) Share-based Compensation (2010 - 2026)

Vanda Pharmaceuticals has disclosed Share-based Compensation across 17 years of filings, most recently posting $2.6 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $2.6 million, down 13.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.1 million (down 23.29% YoY), and the FY2025 annual result was $9.5 million, down 23.79% from the prior year.
• Share-based Compensation came in at $2.6 million for Q1 2026 at Vanda Pharmaceuticals, up from $2.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $4.8 million in Q1 2022 to a low of $2.1 million in Q2 2025.
• The 5-year median for Share-based Compensation is $3.2 million (2023), against an average of $3.2 million.
• Across the five-year window, Share-based Compensation increased 22.23% in 2022 and slipped 29.58% in 2025, its largest moves.
• Vanda Pharmaceuticals' Share-based Compensation stood at $3.8 million in 2022, then retreated by 13.48% to $3.3 million in 2023, then fell by 12.53% to $2.9 million in 2024, then fell by 20.19% to $2.3 million in 2025, then climbed by 12.17% to $2.6 million in 2026.
• The last three Share-based Compensation figures came in at $2.6 million (Q1 2026), $2.3 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.